David D. O’toole Purchases 1,000 Shares of AVITA Medical, Inc. (NASDAQ:RCEL) Stock

AVITA Medical, Inc. (NASDAQ:RCEL) CFO David D. O’toole bought 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The stock was purchased at an average price of $10.25 per share, with a total value of $10,250.00. Following the completion of the purchase, the chief financial officer now directly owns 24,734 shares of the company’s stock, valued at $253,523.50. This represents a 4.21 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

AVITA Medical Stock Performance

Shares of NASDAQ:RCEL opened at $9.95 on Friday. The business’s fifty day moving average price is $10.45 and its two-hundred day moving average price is $10.62. AVITA Medical, Inc. has a fifty-two week low of $7.51 and a fifty-two week high of $18.93. The stock has a market capitalization of $260.87 million, a price-to-earnings ratio of -4.16 and a beta of 1.55. The company has a debt-to-equity ratio of 9.39, a current ratio of 2.83 and a quick ratio of 2.47.

AVITA Medical (NASDAQ:RCEL) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). The company had revenue of $18.41 million during the quarter, compared to the consensus estimate of $18.40 million. AVITA Medical had a negative net margin of 96.26% and a negative return on equity of 337.91%. As a group, analysts predict that AVITA Medical, Inc. will post -1.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RCEL has been the subject of a number of recent research reports. Lake Street Capital cut their target price on AVITA Medical from $20.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. D. Boral Capital lowered their price target on AVITA Medical from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price target on shares of AVITA Medical in a research report on Tuesday, December 24th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $12.00 price target (up from $9.00) on shares of AVITA Medical in a research report on Friday, November 8th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.25.

Institutional Trading of AVITA Medical

Several large investors have recently made changes to their positions in the business. AlphaQuest LLC grew its holdings in shares of AVITA Medical by 24.7% during the fourth quarter. AlphaQuest LLC now owns 9,378 shares of the company’s stock worth $120,000 after purchasing an additional 1,858 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of AVITA Medical by 48.0% during the fourth quarter. Russell Investments Group Ltd. now owns 7,164 shares of the company’s stock worth $92,000 after purchasing an additional 2,324 shares during the last quarter. FMR LLC grew its holdings in shares of AVITA Medical by 126.9% during the third quarter. FMR LLC now owns 4,248 shares of the company’s stock worth $46,000 after purchasing an additional 2,376 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of AVITA Medical during the fourth quarter worth $38,000. Finally, Huntington National Bank bought a new stake in shares of AVITA Medical during the third quarter worth $32,000. Institutional investors own 27.66% of the company’s stock.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.